Puma Biotech Investors Ink $54M Deal Over Drug Statements
Law 360
DECEMBER 14, 2021
Investors alleging that Puma Biotechnology Inc. misstated the effectiveness of a breast cancer treatment, causing the biopharmaceutical company's share price to drop, asked a California federal judge Monday to preliminarily approve a $54.2
Let's personalize your content